Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22281233 | 0.91 | NTRK1 (0.36) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL22281229 | 0.91 | MAPK1 (0.38) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL22280890 | 0.89 | MAPK1 (0.37) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL22280906 | 0.88 | MAPK1 (0.36) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL19492795 | 0.80 | MAPK1 (0.40) | MAPK1NTRK1PDE2A | |
| SCHEMBL20768124 | 0.80 | MAPK1 (0.40) | MAPK1NTRK1PDE2A | |
| SCHEMBL22281402 | 0.79 | MAPK1 (0.35) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL22281266 | 0.79 | MAPK1 (0.35) | MAPK1TP53NTRK1MAPTALDH1A1 | |
| SCHEMBL22280903 | 0.78 | MAPK1 (0.36) | MAPK1NTRK1MAPTALDH1A1LMNA | |
| SCHEMBL22280891 | 0.77 | MAPK1 (0.38) | MAPK1NTRK1MAPTLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPK1 3964/4885TP53 2133/4885NTRK1 4374/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPK1 3487/4885TP53 2346/4885NTRK1 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.